Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 3 3Phase 2 3Phase 1/2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 3Peritoneal Neoplasms 1Ovarian Neoplasms 1Colorectal Neoplasms 1

Interventions

Carboplatin 190Cisplatin 156Pemetrexed 151Paclitaxel 127Docetaxel 109pembrolizumab 87Gemcitabine 73Erlotinib Hydrochloride 44Radiotherapy 39Vinorelbine 35Gefitinib 34durvalumab 31Bevacizumab 28Nivolumab 26Drug Therapy 23atezolizumab 22osimertinib 19130-nm albumin-bound paclitaxel 19tislelizumab 16Crizotinib 16Radiosurgery 15Etoposide 14Surgical Procedures, Operative 11Afatinib 11Ipilimumab 10icotinib 9aumolertinib 9Albumin-Bound Paclitaxel 9Specimen Handling 8Observation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Non-Small-Cell Lung × nintedanib × Clear all
NCT02231164 2025-02-13

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

Boehringer Ingelheim

Phase 3 Terminated
12 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00805194 2018-12-05

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Boehringer Ingelheim

Phase 3 Completed
1,314 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00806819 2017-02-02

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Boehringer Ingelheim

Phase 3 Completed
718 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡